{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:24:36Z","timestamp":1762431876145,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"UBI Pharma Inc"},{"name":"Hsinchu, Taiwan"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jmii.2020.06.010","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T02:19:24Z","timestamp":1594088364000},"page":"944-951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2204-6355","authenticated-orcid":false,"given":"Wei-Chieh","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Kai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1858-6367","authenticated-orcid":false,"given":"Sung-Hsi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9940-0850","authenticated-orcid":false,"given":"Shu-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyh-Tyan","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0074-7721","authenticated-orcid":false,"given":"Hsin-Yun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2016","series-title":"Combined global demand forecasts for antiretroviral medicines and HIV diagnostics in low- and middle-income countries from 2015 to 2020","author":"World Health Organization","key":"10.1016\/j.jmii.2020.06.010_bib1"},{"key":"10.1016\/j.jmii.2020.06.010_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10461-016-1545-0","article-title":"The role of ARV associated adverse drug reactions in influencing adherence among HIV-infected individuals: a systematic review and qualitative meta-synthesis","volume":"21","author":"Li","year":"2017","journal-title":"AIDS Behav"},{"key":"10.1016\/j.jmii.2020.06.010_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/QAD.0000000000000911","article-title":"Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study","volume":"30","author":"van Lunzen","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2020.06.010_bib4","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1086\/497835","article-title":"Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring","volume":"41","author":"Gutierrez","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2020.06.010_bib5","doi-asserted-by":"crossref","first-page":"e0171596","DOI":"10.1371\/journal.pone.0171596","article-title":"Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naive HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan","volume":"12","author":"Wu","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.jmii.2020.06.010_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1473-3099(15)70060-5","article-title":"Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study","volume":"15","author":"Carey","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2020.06.010_bib7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/QAI.0b013e3181b061e6","article-title":"Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations","volume":"52","author":"van Luin","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jmii.2020.06.010_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3851\/IMP1742","article-title":"Successful efavirenz dose reduction guided by therapeutic drug monitoring","volume":"16","author":"Fayet Mello","year":"2011","journal-title":"Antivir Ther"},{"issue":"1","key":"10.1016\/j.jmii.2020.06.010_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jmii.2018.05.001","article-title":"Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: a prospective study","volume":"53","author":"Huang","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2020.06.010_bib10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QAD.0000000000002067","article-title":"Randomized clinical trial on efficacy of fixed-dose efavirenz\/tenofovir\/emtricitabine on alternate days versus continuous treatment","volume":"33","author":"Bellagamba","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2020.06.010_bib11","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1097\/QAD.0000000000001843","article-title":"A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz\/emtricitabine\/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity","volume":"32","author":"Rojas","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2020.06.010_bib12","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/ciy161","article-title":"Pharmacokinetics, pharmacodynamics, and pharmacogenetics of efavirenz 400 mg once daily during pregnancy and post-partum","volume":"67","author":"Lamorde","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2020.06.010_bib13","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/cid\/ciy491","article-title":"Pharmacokinetics of efavirenz 400 mg once daily coadministered with isoniazid and rifampicin in human immunodeficiency virus-infected individuals","volume":"68","author":"Cerrone","year":"2019","journal-title":"Clin Infect Dis"},{"year":"2019","series-title":"Update of recommendations on first- and second-line antiretroviral regimens","author":"World Health Organization","key":"10.1016\/j.jmii.2020.06.010_bib14"},{"key":"10.1016\/j.jmii.2020.06.010_bib15","doi-asserted-by":"crossref","first-page":"e1677","DOI":"10.1097\/MD.0000000000001677","article-title":"Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens","volume":"94","author":"Clay","year":"2015","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jmii.2020.06.010_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/jac5.1284","article-title":"Implementation and outcomes of a therapeutic drug monitoring program for antifungal and antiretroviral agents in a tertiary medical center in Taiwan","author":"Lin","year":"2020","journal-title":"J Am Coll Clin Pharm"},{"key":"10.1016\/j.jmii.2020.06.010_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jchromb.2006.03.014","article-title":"Simple and rapid liquid chromatography method for determination of efavirenz in plasma","volume":"835","author":"Ramachandran","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.jmii.2020.06.010_bib18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/cpt.156","article-title":"Pharmacokinetic and pharmacodynamic comparison of once-daily efavirenz (400 mg vs. 600 mg) in treatment-naive HIV-infected patients: results of the ENCORE1 study","volume":"98","author":"Dickinson","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jmii.2020.06.010_bib19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40262-015-0360-5","article-title":"Comprehensive pharmacokinetic, pharmacodynamic and pharmacogenetic evaluation of once-daily efavirenz 400 and 600 mg in treatment-naive HIV-infected patients at 96 Weeks: results of the ENCORE1 study","volume":"55","author":"Dickinson","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jmii.2020.06.010_bib20","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1128\/AAC.46.8.2687-2691.2002","article-title":"Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor","volume":"46","author":"Pilon","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2020.06.010_bib21","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s10461-011-9939-5","article-title":"A systematic review of the psychiatric side-effects of efavirenz","volume":"15","author":"Kenedi","year":"2011","journal-title":"AIDS Behav"},{"key":"10.1016\/j.jmii.2020.06.010_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2020.06.010_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2334-14-26","article-title":"Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naive or switching for simplification HIV-infected patients","volume":"14","author":"Fabbiani","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jmii.2020.06.010_bib24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/PPA.S31385","article-title":"Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era","volume":"6","author":"Sterrantino","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jmii.2020.06.010_bib25","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jmii.2019.05.011","article-title":"Prevalence and related drug cost of comorbidities in HIV-infected patients receiving highly active antiretroviral therapy in Taiwan: a cross-sectional study","volume":"52","author":"Yang","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2020.06.010_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11904-016-0331-y","article-title":"Atherosclerotic cardiovascular disease and anti-retroviral therapy","volume":"13","author":"Kaplan-Lewis","year":"2016","journal-title":"Curr HIV AIDS Rep"},{"key":"10.1016\/j.jmii.2020.06.010_bib27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/cid\/ciu234","article-title":"Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials","volume":"59","author":"Tebas","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2020.06.010_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1310\/hct1001-1","article-title":"Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels","volume":"10","author":"Hill","year":"2009","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jmii.2020.06.010_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/hiv.12607","article-title":"Prospective plasma efavirenz concentration assessment in Chinese HIV-infected adults enrolled in a large multicentre study","author":"Guo","year":"2018","journal-title":"HIV Med"},{"key":"10.1016\/j.jmii.2020.06.010_bib30","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/00002030-200403260-00017","article-title":"Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients","volume":"18","author":"Negredo","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2020.06.010_bib31","doi-asserted-by":"crossref","first-page":"e2385","DOI":"10.1097\/MD.0000000000002385","article-title":"Plasma efavirenz concentrations are associated with lipid and glucose concentrations","volume":"95","author":"Sinxadi","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jmii.2020.06.010_bib32","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2125.2006.02619.x","article-title":"Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients","volume":"61","author":"Pereira","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jmii.2020.06.010_bib33","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.atherosclerosis.2008.09.016","article-title":"Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice","volume":"204","author":"Tohyama","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jmii.2020.06.010_bib34","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/14740338.2019.1644317","article-title":"Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment","volume":"18","author":"Lagathu","year":"2019","journal-title":"Expet Opin Drug Saf"},{"year":"2019","series-title":"HIV market report: the state of the antiretroviral drug market in low- and middle-income countries","author":"Clinton Health Access Initiative I","key":"10.1016\/j.jmii.2020.06.010_bib35"},{"key":"10.1016\/j.jmii.2020.06.010_bib36","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","author":"Sax","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2020.06.010_bib37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijid.2019.12.029","article-title":"Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to coformulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide","volume":"92","author":"Kuo","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jmii.2020.06.010_bib38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fphar.2019.00199","article-title":"The utility of efavirenz-based prophylaxis Against HIV infection. A systems pharmacological analysis","volume":"10","author":"Duwal","year":"2019","journal-title":"Front Pharmacol"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118220301511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118220301511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:28:07Z","timestamp":1761658087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118220301511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1684118220301511"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2020.06.010","relation":{},"ISSN":["1684-1182"],"issn-type":[{"type":"print","value":"1684-1182"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2020.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}